Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Population Pharmacokinetics (PPK) and Exposure-Response to Support Body Surface Area (BSA)-Based Dosing of Brentuximab Vedotin in Pediatric Patients with Advanced-Stage Newly-Diagnosed Hodgkin Lymphoma (HL)

Xiaofei Zhou, Diane R Mould, Anna R K Franklin, Lia Gore, Xiang Bai, Neeraj Gupta

Blood (2022) 140 (Supplement 1): 3724–3725.

https://doi.org/10.1182/blood-2022-160105

Published: 2022

Journal Articles

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Blood (2015) 126 (23): 341.

https://doi.org/10.1182/blood.V126.23.341.341

Published: 2015

Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 3027.

https://doi.org/10.1182/blood.V122.21.3027.3027

Published: 2013

Journal Articles

Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors

Ely Benaim, MD, Xiaofei Zhou, PhD, Hua Liu, PhD, E. Jane Leonard, MSc, Eric Freedland, Liviu Niculescu

Blood (2012) 120 (21): 3683.

https://doi.org/10.1182/blood.V120.21.3683.3683

Published: 2012

Journal Articles

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Jonathan Friedberg, MD, Daruka Mahadevan, MD, PhD, JungAh Jung, PhD, Daniel O. Persky, MD, Izidore S Lossos, MD, Hadi Danaee, SD, Xiaofei Zhou, PhD, E Jane Leonard, Steven H. Bernstein

Blood (2011) 118 (21): 95.

https://doi.org/10.1182/blood.V118.21.95.95

Published: 2011

Journal Articles

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Kevin R. Kelly, MD, Swaminathan Padmanabhan, MBBS, MD, André Goy, MD, Jesus G. Berdeja, MD, Craig B. Reeder, MD, Kevin T. McDonagh, MD, Xiaofei Zhou, PhD, Hadi Danaee, SD, Hugh Xiao, PhD, Ely Benaim, MD, Thomas C. Shea, MD

Blood (2011) 118 (21): 2477.

https://doi.org/10.1182/blood.V118.21.2477.2477

Published: 2011

Journal Articles

Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.

Swaminathan Padmanabhan, MBBS, MD, Thomas C. Shea, MD, Julie M. Vose, MD, Craig B. Reeder, MD, Jesus G Berdeja, MD, Kevin T. McDonagh, MD, Andre Goy, MD, Kevin R Kelly, MD, Xiaofei Zhou, PhD, Hua Liu, PhD, Howard Fingert, MD, Nathan Fowler, MD

Blood (2010) 116 (21): 2799.

https://doi.org/10.1182/blood.V116.21.2799.2799

Published: 2010

NARROW

Population Pharmacokinetics (PPK) and Exposure-Response to Support Body Surface Area (BSA)-Based Dosing of Brentuximab Vedotin in Pediatric Patients with Advanced-Stage Newly-Diagnosed Hodgkin Lymphoma (HL)

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Population Pharmacokinetics (PPK) and Exposure-Response to Support Body Surface Area (BSA)-Based Dosing of Brentuximab Vedotin in Pediatric Patients with Advanced-Stage Newly-Diagnosed Hodgkin Lymphoma (HL)

First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors

Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only